A case for conducting business-to-business experiments with multi-arm multi-stage adaptive designs

被引:1
|
作者
Legare, Jonathan [1 ]
Yao, Ping [1 ]
Lo, Victor S. Y. [1 ]
机构
[1] Fidel Investments, 245 Summer St, Boston, MA 02210 USA
关键词
Randomized controlled trial; Multi-arm multi-stage; Adaptive design; Simulation study; Experimental design; Business-to-business; CLINICAL-TRIALS;
D O I
10.1057/s41270-022-00177-4
中图分类号
F [经济];
学科分类号
02 ;
摘要
Many businesses conduct experiments to scientifically test, measure, and optimize decisions in areas like sales, marketing, and operations efficiency. While randomized controlled trials (RCTs) or A/B tests are the dominant method for conducting business experiments especially for business-to-consumer marketing, adaptive designs have yet to make extensive inroads outside of the pharmaceutical and medical industries. In this study, we aim to raise awareness of the applicability and advantages of multi-arm multi-stage adaptive designs outside of clinical settings and we use simulations to demonstrate the value of these designs to modern business experiments, with a focus on business-to-business experiments such as testing alternative sales techniques. Our simulation results show that, compared to RCT, multi-arm multi-stage adaptive designs (MAMS) can reduce the sample size requirements and expected time to experiment completion whilst maintaining a similar level of statistical power. We also demonstrate that these benefits can translate into actual cost savings in conjunction with shorter time to market, resulting in higher overall efficiency over the traditional RCTs. MAMS serves as a strong alternative methodology in experiments where not all customers can be contacted at once such as business-to-business campaigns and general live channel programs which typically take weeks to months to complete.
引用
收藏
页码:490 / 502
页数:13
相关论文
共 50 条
  • [41] ON THE CONSTRUCTION OF A MULTI-STAGE, MULTI-PERSON BUSINESS GAME
    BELLMAN, R
    CLARK, CE
    MALCOLM, DG
    CRAFT, CJ
    RICCIARDI, FM
    OPERATIONS RESEARCH, 1957, 5 (04) : 469 - 503
  • [42] Two-stage response adaptive randomization designs for multi-arm trials with binary outcome
    Lu, Xinlin
    Shan, Guogen
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2024, 34 (04) : 526 - 538
  • [43] A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection
    Magirr, D.
    Jaki, T.
    Whitehead, J.
    BIOMETRIKA, 2012, 99 (02) : 494 - 501
  • [44] A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis
    Daniel J Bratton
    Patrick PJ Phillips
    Mahesh KB Parmar
    BMC Medical Research Methodology, 13
  • [45] A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis
    Bratton, Daniel J.
    Phillips, Patrick P. J.
    Parmar, Mahesh K. B.
    BMC MEDICAL RESEARCH METHODOLOGY, 2013, 13
  • [46] Funding and Sustainability Challenges in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease
    Gonzalez-Robles, C.
    Ahmed, J.
    Bale, C.
    Chapman, R.
    Clegg, S.
    Deeson, E.
    Ellis-Doyle, R.
    Greaves, V.
    Handley, J.
    Henderson, E.
    Matthews, K.
    Medd-Phillips, S.
    Miller, L.
    Mills, G.
    Rudiger, J.
    Zeissler, M. L.
    Carroll, C.
    Foltynie, T.
    Gandhi, S.
    Duffen, J.
    MOVEMENT DISORDERS, 2022, 37 : S328 - S329
  • [47] Controlling the family-wise error rate in multi-arm, multi-stage trials
    Crouch, Luis A.
    Dodd, Lori E.
    Proschan, Michael A.
    CLINICAL TRIALS, 2017, 14 (03) : 237 - 245
  • [48] Simulation optimization for Bayesian multi-arm multi-stage clinical trial with binary endpoints
    Yu, Zhenning
    Ramakrishnan, Viswanathan
    Meinzer, Caitlyn
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2019, 29 (02) : 306 - 317
  • [49] Adding experimental treatment arms to multi-arm multi-stage platform trials in progress
    Burnett, Thomas
    Koenig, Franz
    Jaki, Thomas
    STATISTICS IN MEDICINE, 2024, 43 (18) : 3447 - 3462
  • [50] Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study
    Thomas Jaki
    James M. S. Wason
    BMC Cardiovascular Disorders, 18